FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2300290078> ?p ?o ?g. }

• W2300290078 endingPage "3331" @default.
• W2300290078 startingPage "3319" @default.
• W2300290078 abstract "Abstract Proteasome-regulated NF-κB has been shown to be important for cell survival in T-cell lymphoma and Hodgkin lymphoma models. Several new small-molecule proteasome inhibitors are under various stages of active preclinical and clinical development. We completed a comprehensive preclinical examination of the efficacy and associated biologic effects of a second-generation proteasome inhibitor, ixazomib, in T-cell lymphoma and Hodgkin lymphoma cells and in vivo SCID mouse models. We demonstrated that ixazomib induced potent cell death in all cell lines at clinically achievable concentrations. In addition, it significantly inhibited tumor growth and improved survival in T-cell lymphoma and Hodgkin lymphoma human lymphoma xenograft models. Through global transcriptome analyses, proteasomal inhibition showed conserved overlap in downregulation of cell cycle, chromatin modification, and DNA repair processes in ixazomib-sensitive lymphoma cells. The predicted activity for tumor suppressors and oncogenes, the impact on “hallmarks of cancer,” and the analysis of key significant genes from global transcriptome analysis for ixazomib strongly favored tumor inhibition via downregulation of MYC and CHK1, its target genes. Furthermore, in ixazomib-treated lymphoma cells, we identified that CHK1 was involved in the regulation of MYC expression through chromatin modification involving histone H3 acetylation via chromatin immunoprecipitation. Finally, using pharmacologic and RNA silencing of CHK1 or the associated MYC-related mechanism, we demonstrated synergistic cell death in combination with antiproteasome therapy. Altogether, ixazomib significantly downregulates MYC and induces potent cell death in T-cell lymphoma and Hodgkin lymphoma, and we identified that combinatorial therapy with anti-CHK1 treatment represents a rational and novel therapeutic approach. Cancer Res; 76(11); 3319–31. ©2016 AACR." @default.
• W2300290078 created "2016-06-24" @default.
• W2300290078 creator A5001202734 @default.
• W2300290078 creator A5007720255 @default.
• W2300290078 creator A5012156971 @default.
• W2300290078 creator A5034908463 @default.
• W2300290078 creator A5034948336 @default.
• W2300290078 creator A5035252288 @default.
• W2300290078 creator A5042024184 @default.
• W2300290078 creator A5063400337 @default.
• W2300290078 creator A5064091455 @default.
• W2300290078 creator A5064711111 @default.
• W2300290078 creator A5065530824 @default.
• W2300290078 creator A5077595545 @default.
• W2300290078 creator A5078559032 @default.
• W2300290078 date "2016-05-31" @default.
• W2300290078 modified "2023-10-12" @default.
• W2300290078 title "Proteasomal Inhibition by Ixazomib Induces CHK1 and MYC-Dependent Cell Death in T-cell and Hodgkin Lymphoma" @default.
• W2300290078 cites W1603624799 @default.
• W2300290078 cites W1909862186 @default.
• W2300290078 cites W1965254413 @default.
• W2300290078 cites W1972550125 @default.
• W2300290078 cites W1986141922 @default.
• W2300290078 cites W1986743724 @default.
• W2300290078 cites W1992617765 @default.
• W2300290078 cites W1996949194 @default.
• W2300290078 cites W2001045944 @default.
• W2300290078 cites W2002419133 @default.
• W2300290078 cites W2009426416 @default.
• W2300290078 cites W2015668100 @default.
• W2300290078 cites W2016859030 @default.
• W2300290078 cites W2018577785 @default.
• W2300290078 cites W2024833882 @default.
• W2300290078 cites W2025523323 @default.
• W2300290078 cites W2028154024 @default.
• W2300290078 cites W2038994136 @default.
• W2300290078 cites W2041381844 @default.
• W2300290078 cites W2057290270 @default.
• W2300290078 cites W2063393072 @default.
• W2300290078 cites W2081446512 @default.
• W2300290078 cites W2085144387 @default.
• W2300290078 cites W2086941505 @default.
• W2300290078 cites W2087351356 @default.
• W2300290078 cites W2089743544 @default.
• W2300290078 cites W2092648714 @default.
• W2300290078 cites W2094618322 @default.
• W2300290078 cites W2097948046 @default.
• W2300290078 cites W2099395323 @default.
• W2300290078 cites W2104979060 @default.
• W2300290078 cites W2109371953 @default.
• W2300290078 cites W2113805244 @default.
• W2300290078 cites W2114496414 @default.
• W2300290078 cites W2117692326 @default.
• W2300290078 cites W2119605929 @default.
• W2300290078 cites W2120525778 @default.
• W2300290078 cites W2120865735 @default.
• W2300290078 cites W2126373050 @default.
• W2300290078 cites W2129496479 @default.
• W2300290078 cites W2130649080 @default.
• W2300290078 cites W2131206730 @default.
• W2300290078 cites W2134847995 @default.
• W2300290078 cites W2135658123 @default.
• W2300290078 cites W2142415307 @default.
• W2300290078 cites W2145264022 @default.
• W2300290078 cites W2151918127 @default.
• W2300290078 cites W2157895537 @default.
• W2300290078 cites W2166766006 @default.
• W2300290078 cites W2168980644 @default.
• W2300290078 cites W2191026405 @default.
• W2300290078 cites W2326148782 @default.
• W2300290078 cites W51542665 @default.
• W2300290078 doi "https://doi.org/10.1158/0008-5472.can-15-2477" @default.
• W2300290078 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5315412" @default.
• W2300290078 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/26988986" @default.
• W2300290078 hasPublicationYear "2016" @default.
• W2300290078 type Work @default.
• W2300290078 sameAs 2300290078 @default.
• W2300290078 citedByCount "34" @default.
• W2300290078 countsByYear W23002900782016 @default.
• W2300290078 countsByYear W23002900782017 @default.
• W2300290078 countsByYear W23002900782018 @default.
• W2300290078 countsByYear W23002900782019 @default.
• W2300290078 countsByYear W23002900782020 @default.
• W2300290078 countsByYear W23002900782021 @default.
• W2300290078 countsByYear W23002900782022 @default.
• W2300290078 countsByYear W23002900782023 @default.
• W2300290078 crossrefType "journal-article" @default.
• W2300290078 hasAuthorship W2300290078A5001202734 @default.
• W2300290078 hasAuthorship W2300290078A5007720255 @default.
• W2300290078 hasAuthorship W2300290078A5012156971 @default.
• W2300290078 hasAuthorship W2300290078A5034908463 @default.
• W2300290078 hasAuthorship W2300290078A5034948336 @default.
• W2300290078 hasAuthorship W2300290078A5035252288 @default.
• W2300290078 hasAuthorship W2300290078A5042024184 @default.
• W2300290078 hasAuthorship W2300290078A5063400337 @default.
• W2300290078 hasAuthorship W2300290078A5064091455 @default.
• W2300290078 hasAuthorship W2300290078A5064711111 @default.
• W2300290078 hasAuthorship W2300290078A5065530824 @default.

• next